| P2093 | author name string | Eric Kim | |
| | John B Miller | |
| | Jose M Ruiz-Moreno | |
| | Elizabeth J Rossin | |
| | Joseph F Arboleda-Velasquez | |
| | Dean Eliott | |
| | Leo A Kim | |
| | Lucia Gonzalez-Buendia | |
| | Santiago Delgado-Tirado | |
| | Heuy-Ching Wang | |
| | Guannan Zhao | |
| | Dhanesh Amarnani | |
| | Brandon V Duffy | |
| | Daniela Isaacs-Bernal | |
| | David Leyton-Cifuentes | |
| | Hannah A B Whitmore | |
| | Leslie Ramos | |
| | Natalia Chmielewska | |
| | Said Arevalo-Alquichire | |
| | Whitney A Greene | |
| P2860 | cites work | The basics of epithelial-mesenchymal transition | Q24652992 |
| | Molecular mechanisms of epithelial-mesenchymal transition | Q27013743 |
| | DNA recognition by the RUNX1 transcription factor is mediated by an allosteric transition in the RUNT domain and by DNA bending | Q27639779 |
| | Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research | Q29547313 |
| | Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers | Q30276341 |
| | Endothelio-mesenchymal interaction controls runx1 expression and modulates the notch pathway to initiate aortic hematopoiesis | Q30576002 |
| | Müller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data | Q30782341 |
| | Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy | Q30844688 |
| | Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data | Q30951695 |
| | Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. | Q33303554 |
| | Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition | Q33566597 |
| | Experimental posterior penetrating eye injury in the rabbit. I. Method of production and natural history | Q33651343 |
| | Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction | Q34388355 |
| | Microemulsions as ocular drug delivery systems: recent developments and future challenges | Q34572807 |
| | Proliferative vitreoretinopathy: risk factors and pathobiology | Q34572836 |
| | A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics | Q35560465 |
| | The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. | Q36798094 |
| | Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid | Q37250122 |
| | Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter | Q37347018 |
| | Transient RUNX1 Expression during Early Mesendodermal Differentiation of hESCs Promotes Epithelial to Mesenchymal Transition through TGFB2 Signaling | Q37410179 |
| | Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. | Q37873557 |
| | Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. | Q38050745 |
| | Pathophysiology of proliferative vitreoretinopathy in retinal detachment | Q38104002 |
| | Current anti-vascular endothelial growth factor dosing regimens: benefits and burden | Q38104049 |
| | Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature | Q38110731 |
| | The retinal pigment epithelium: an important player of retinal disorders and regeneration | Q38123624 |
| | Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? | Q38177558 |
| | Clinical management of proliferative vitreoretinopathy: an update | Q38324784 |
| | Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences | Q38553849 |
| | Pharmacokinetic aspects of retinal drug delivery. | Q39059478 |
| | Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment | Q39713018 |
| | Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant | Q40788113 |
| | Traction retinal detachment. XLIX Edward Jackson Memorial Lecture | Q40869093 |
| | Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy | Q41257017 |
| | RUNX1 and breast cancer | Q42334131 |
| | Up-regulation of alpha-smooth muscle actin in cardiomyocytes from non-hypertrophic and non-failing transgenic mouse hearts expressing N-terminal truncated cardiac troponin I. | Q42846330 |
| | Chorioretinectomy for perforating or severe intraocular foreign body injuries | Q43162367 |
| | Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial | Q43653227 |
| | A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy | Q45175644 |
| | The SPOTS System: An Ocular Scoring System Optimized for Use in Modern Preclinical Drug Development and Toxicology | Q46241394 |
| | Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. | Q46515273 |
| | Myofibroblast and extracellular matrix origins in proliferative vitreoretinopathy | Q46621860 |
| | In vivo models of proliferative vitreoretinopathy | Q46951405 |
| | Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. | Q47954026 |
| | Glial cell reactivity in a porcine model of retinal detachment | Q48567647 |
| | 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations | Q49380785 |
| | RUNX1 Mutations in Inherited and Sporadic Leukemia | Q50074717 |
| | Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. | Q50990756 |
| | Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis. | Q51063080 |
| | SMOKING IS A RISK FACTOR FOR PROLIFERATIVE VITREORETINOPATHY AFTER TRAUMATIC RETINAL DETACHMENT. | Q51739219 |
| | RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. | Q52568539 |
| | Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes. | Q52686831 |
| | Perforating globe injuries during operation Iraqi Freedom. | Q53135530 |
| | Effect of Serial Intrasilicone Oil Bevacizumab Injections in Eyes With Recurrent Proliferative Vitreoretinopathy Retinal Detachment. | Q53192689 |
| | Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ. | Q55400547 |
| | Biospecimen reporting for improved study quality (BRISQ) | Q57419587 |
| | Comparison of Surgically Excised Premacular Membranes in Eyes with Macular Pucker and Proliferative Vitreoretinopathy | Q58102315 |
| | A comparison of different cellular inocula in an experimental model of massive periretinal proliferation | Q70362693 |
| | Simulation of Massive Periretinal Proliferation by Autotransplantation of Retinal Pigment Epithelial Cells in Rabbits | Q70782652 |
| | 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite | Q71307535 |
| | Risk factors for proliferative vitreoretinopathy | Q74429379 |
| | Proliferative vitreoretinopathy: an overview | Q77144020 |
| | [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis] | Q88223145 |
| | Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations | Q88558571 |
| | RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner | Q91386039 |
| | Dieckol inhibits non-small-cell lung cancer cell proliferation and migration by regulating the PI3K/AKT signaling pathway | Q91765967 |
| | RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer | Q92348349 |
| P433 | issue | 1 | |
| P921 | main subject | proliferative vitreoretinopathy | Q7249608 |
| P304 | page(s) | 20554 | |
| P577 | publication date | 2020-11-30 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy | |
| P478 | volume | 10 | |